arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

BIOFORCE NANOSCIENCES HOLDINGS, INC.

BFNH

— Price unavailable

10 Visible periods

23 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Good

Bullish

auto_awesome

Analytical Summary

BIOFORCE NANOSCIENCES HOLDINGS, INC. shows strong fundamentals with top-quartile Return on Common Equity (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap —

Dividend Yield —

Revenue Growth None

Op. Margin None

ROIC None

FCF / Share $-0.00 ↗

Trailing P/E —

Price / Book —

FCF Yield —

Debt / Equity —

info Valuation on last close.

10-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$17.77K

↑ +9.0% —

Net Income Profit after all expenses

$-1.29M

↓ -163.4% —

Operating Margin Operating profit as % of sales

-261.8%

↑ +36.0% —

FCF / Share Free cash flow per share

$-0.00

↑ +6.2% —

trending_up

Bullish Indicators

Return on Common Equity (%)Return on Common Equity (%) is in the top quartile

warning

Bearish Risks

No bearish risks detected.

Health Breakdown

Returns ↑

100

Cash Quality ↓

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗
Revenue Growth YoY (%)	—	—	—	—	—	—	9.0% Fair Fair Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+80%)	262.4% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+5149%)	—	—
EPS Growth YoY (%)	-100.0% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	0.0% Caution Caution Year-over-year change in earnings per share Optimal: > 10%	0.0% Caution Caution Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—	—	—
Net Income Growth YoY (%)	-163.4% Weak ↓ Weak Declining Year-over-year change in net income	-3.9% Weak ↓ Weak Declining Year-over-year change in net income	2.8% Caution ↑ Caution Improving Year-over-year change in net income	3.3% Caution ↑ Caution Improving Year-over-year change in net income	99.7% Excellent ↑ Excellent Improving Year-over-year change in net income	-340285.4% Weak ↓ Weak Declining Year-over-year change in net income	31.3% Excellent Excellent Year-over-year change in net income	-116.7% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	6.2% Fair ↑ Fair Improving Year-over-year change in free cash flow	-31.2% Weak Weak Year-over-year change in free cash flow	31.7% Excellent Excellent Year-over-year change in free cash flow	—	—	—	—	—	—	—

💰 Are margins durable? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗
Operating Margin (%) (%)	—	—	—	—	—	—	-261.8% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2282%)	-409.2% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-3510%)	—	—
Effective Tax Rate (%) (%)	—	—	—	—	—	—	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—
Profit Margin (%) (%)	—	—	—	—	—	—	-261.8% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-3373%)	-415.3% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-5291%)	—	—
FCF Margin (%) (%)	—	—	—	—	—	—	-137.2% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	-383.0% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	—
FCF / Net Income (x)	0.05x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.12x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.10x Weak → Weak Stable Free cash flow relative to reported net income Optimal: > 1x	0.14x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.15x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.00x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.52x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.92x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.83x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗
Return on Invested Capital (%)	—	—	—	—	—	—	-98.4% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-223.9% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	-301.1% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	—	—	—	—	—	—	-79.0% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-190.0% Weak Weak Operating profit relative to total assets Optimal: > 10%	-149.5% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	208.9% Excellent ↑ Excellent Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+1292%)	21.3% Excellent ↓ Excellent Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+42%)	25.9% Excellent ↓ Excellent Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+73%)	36.0% Excellent ↑ Excellent Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+140%)	58.2% Excellent ↑ Excellent Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+288%)	—	-98.4% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-756%)	-227.3% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1615%)	—	—

⚖️ Is the balance sheet risky? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗
Net Debt (USD)	$-786.00	$-862.00	$-638.00	$-734.00	$-11.11K	$-39.87K	$-52.90K	$-29.39K	$-14.32K	$-14.32K

📊 What does each share earn? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗
Basic EPS, GAAP (USD)	$-0.04	$-0.02	$-0.02	$-0.02	—	—	—	—	—	—
Free Cash Flow per Share (USD)	$-0.00	$-0.00	$-0.00	$-0.00	—	—	—	—	—	—
Book Value per Share (USD)	$-0.02	$-0.08	$-0.06	$-0.05	$-0.03	$-0.01	$0.00	$0.00	$0.00	—
Tangible Book Value per Share (USD)	$-0.02	$-0.08	$-0.06	$-0.05	$-0.03	$-0.01	$0.00	$0.00	$0.00	—
Basic Weighted Avg Shares (shares)	33.21M	29.27M	29.27M	29.27M	—	—	—	—	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗
Working Capital (USD)	$-618.54K	$-2.30M	$-1.82M	$-1.35M	$-861.86K	$-359.91K	$47.31K	$29.80K	$8.20K	—
Total Equity (USD)	$-618.54K	$-2.30M	$-1.82M	$-1.35M	$-861.86K	$-359.91K	$47.31K	$29.80K	$8.20K	$2.29K

📋 What is driving earnings? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗
Sales/Revenue/Turnover (USD)	—	—	—	—	—	—	$17.77K	$16.31K	$4.50K	—
Net Income, GAAP (USD)	$-1.29M	$-490.44K	$-471.95K	$-485.51K	$-501.95K	$-158.41M	$-46.54K	$-67.74K	$-31.26K	—
Operating Cash Flow (USD)	$-65.15K	$-61.25K	$-46.70K	$-68.39K	$-77.77K	$-80.20K	$-24.38K	$-62.47K	$-25.90K	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 10 years · 37 quarters

BIOFORCE NANOSCIENCES HOLDINGS, INC.

Analytical Summary

10-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare BFNH with peers